H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy.
H2-Histamine receptor blocking agents metiamide and cimetidine were assessed in seven patients with Zollinger-Ellison syndrome (serum gastrin greater than 300 microgram/ml, basal acid output greater than 15 meq/h, ratio of basal acid output to maximal acid output greater than 0.5). Intravenous or oral administration of the drugs lowered acid secretion by at least 70% in all cases. Subsequent treatment of six patients for 3 to 15 months (oral therapy) and one patient for 1 month (intravenous therapy) showed that the drugs abolished symptoms in all seven, abolished diarrhea in five, allowed ulcer healing in six, and were well tolerated without adverse effects in seven. No patient failed to respond to the drug, although one died from tumor progression and two required total gastrectomy for complex reasons. The results indicate that patients with Zollinger-Ellison syndrome can be managed medically and, in light of current mortality trends, gain little from the extra risks attending total gastrectomy.
D000328:Adult; D000368:Aged; D002712:Chlorides / Q000378:metabolism; D002927:Cimetidine / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008785:Metiamide / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D010919:Placebos; D011188:Potassium / Q000378:metabolism; D012965:Sodium Chloride / Q000494:pharmacology / Q000627:therapeutic use; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy*
D002712:Chlorides; D006635:Histamine H2 Antagonists; D010919:Placebos; D008785:Metiamide; D012965:Sodium Chloride; D002927:Cimetidine; D011188:Potassium